WallStreetZenWallStreetZen

NYSE: HAE
Haemonetics Corp Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Haemonetics earnings were $167.7M for the trailing 12 months ending Mar 29, 2025, with 43.5% growth year over year. The latest HAE earnings report on Mar 29, 2025 announced Q1 2025 earnings of $58.0M, up 54.6% from last quarter. For the last reported fiscal year 2025 ending Mar 29, 2025, HAE reported annual earnings of $167.7M, with 42.6% growth. The next HAE earnings date is Aug 7, 2025.

HAE past earnings growth

How has HAE's earnings growth performed historically?

Company
43.53%
Industry
16.35%
Market
33.74%
HAE's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
HAE's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance
HAE's earnings growth is accelerating... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

HAE earnings history

Current Revenue
$1.4B
Current Earnings
$167.7M
Current Profit Margin
12.3%
HAE's has demonstrated consistent long-term... subscribe to Premium to read more.
Long-term Earnings Growth Trend Performance

HAE Return on Equity

Current Company
19.1%
Current Industry
9.7%
Current Market
31.3%
HAE's Return on Equity (19.1%)... subscribe to Premium to read more.
High Return on Equity Performance

HAE undefined

Current Company
6.7%
Current Industry
7.9%
HAE is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when HAE announces earnings.

HAE undefined

Current Company
11.84%
Current Industry
10.3%
HAE has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

HAE vs Medical Stocks

TickerEBITDAEarningsY/Y EarningsEPS
HAE$337.40M$167.68M+17.14%$3.33
NVST-$896.80M-$1.12BN/A-$6.53
XRAY-$511.00M-$908.00MN/A-$4.51
ICUI$287.77M-$93.69MN/A-$3.84
WRBY$28.30M-$14.24MN/A-$0.12
View Top Medical Stocks

HAE earnings dates

Next earnings date
Aug 7, 2025

Haemonetics Earnings Reports & History FAQ

What were Haemonetics's earnings last quarter?

On HAE's earnings call on Invalid Date, Haemonetics (NYSE: HAE) reported Q1 2025 earnings per share (EPS) of $1.17, up 192.5% year over year. Total HAE earnings for the quarter were $57.98 million. In the same quarter last year, Haemonetics's earnings per share (EPS) was $0.40.

If you're new to stock investing, here's how to buy Haemonetics stock.

When does Haemonetics report earnings?

The next HAE earnings call is Invalid Date. Add HAE to your watchlist to be reminded of Haemonetics's next earnings date.

Is Haemonetics profitable or losing money?

As of the last Haemonetics earnings report, Haemonetics is currently profitable. Haemonetics's net profit (also called net income) for the twelve months ending Mar 29, 2025 was $167.68 million, a 42.64% increase year over year.

What was HAE's earnings growth in the past year?

As of Haemonetics's earnings date in Invalid Date, Haemonetics's earnings has grown 43.53% year over year. This is 27.18 percentage points higher than the US Medical Instruments & Supplies industry earnings growth rate of 16.35%. HAE earnings in the past year totalled $167.68 million.

What are Haemonetics's earnings expectations?

The current EPS estimate for Haemonetics's earnings report in Invalid Date is $1.02.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.